Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS · Delayed Price · Currency is USD
0.0450
-0.0038 (-7.71%)
At close: Dec 19, 2025

Inhibitor Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
81016375613
Upgrade
Market Cap Growth
-43.52%-34.56%-57.47%-34.06%332.17%-36.77%
Upgrade
Enterprise Value
546426117
Upgrade
Last Close Price
0.050.060.090.100.150.03
Upgrade
PE Ratio
---3.12--
Upgrade
PB Ratio
2250.905.223.004.49-15.59-3.89
Upgrade
P/TBV Ratio
2250.905.223.004.49--
Upgrade
P/OCF Ratio
---3.17--
Upgrade
Debt / Equity Ratio
20.75--0.05-0.06-0.03
Upgrade
Quick Ratio
34.017.9013.2917.610.050.18
Upgrade
Current Ratio
35.018.0313.4517.640.090.25
Upgrade
Return on Equity (ROE)
-200.97%-91.88%-44.57%517.86%--
Upgrade
Return on Assets (ROA)
-46.88%-31.22%-20.34%-6.83%-213.47%-128.30%
Upgrade
Return on Capital (ROIC)
-129.09%-62.89%-30.42%-15.47%--
Upgrade
Return on Capital Employed (ROCE)
-118.00%-73.40%-41.10%-5.80%52.40%360.60%
Upgrade
Earnings Yield
-44.09%-32.24%-19.12%32.53%-0.53%-8.10%
Upgrade
Buyback Yield / Dilution
-0.15%-0.18%53.04%2.67%-1.16%-0.40%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.